VivoSeq
Oncology

Mycosis Fungoides

51

Pipeline Programs↗

10

Active Trials↗

28

Companies Involved↗

Mycosis Fungoides is a moderately active landscape with 51 programs across 28 companies. The most active players are miRagen Therapeutics, Inc., Regeneron, Bristol-Myers Squibb. 6 therapies are approved with 4 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

60/100

Pipeline Velocity

0/100

Mech. Concentration

15/100

Completion Rate

55/100

Attrition Rate

32/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

miRagen Therapeutics, Inc.

1 program

Phase 1Regeneron logo

Regeneron

1 program

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1E

Eagle Vision Pharmaceutical Corp.

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 1G

Gynecologic Oncology Group

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical2

Mogamulizumab

Kyowa Kirin, Inc.

Dexamethasone Sodium Phosphate

Quince Therapeutics S.p.A.

Phase 113

Cemiplimab

Regeneron

Nivolumab

Bristol-Myers Squibb

Pemetrexed

Eagle Vision Pharmaceutical Corp.

Imiquimod

Bausch Health Americas, Inc.

Gemcitabine

Johnson & Johnson

Phase 226

Alemtuzumab

Genzyme, a Sanofi Company

Brentuximab Vedotin

Pfizer

Pembrolizumab

Merck & Co.

Doxorubicin Hydrochloride

Gynecologic Oncology Group

Lenalidomide

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Phase 34

Humax-CD4

Genmab

Vibramycin

Warner Chilcott

Methoxypsoralen

European Organisation for Research and Treatment of Cancer - EORTC

Hypericin

Soligenix

Approved6

Romidepsin

Teva

Nelarabine

Novartis

Doxycycline

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Prednisone

Roxane Laboratories

Dexamethasone

Aspen Global Incorporated

Analysis

Modality Breakdown

81%

Small molecule

44 of 54 classified programs — the dominant modality here.

19%ALL OTHERSMonoclonal antibody713%Antibody–drug conjugate12%Protein / enzyme12%RNA therapy12%

Small molecule leads; the ring shows all 54 classified programs, each share of the total. Modality classified for 98% of 57 pipeline programs.

Analysis

Trial Status

53

clinical trials

Completed21 · 40%
Terminated14 · 26%
Recruiting6 · 11%
Unknown status5 · 9%
Active, not recruiting4 · 8%
Withdrawn3 · 6%

Clinical Trials

Trial Activity

53 trials

A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT05296304·20 enrolled
Photopheresis in Early-stage Mycosis Fungoides
Recruiting·—·Phase 2·NCT05680558·74 enrolled
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT03587844·58 enrolled
Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
Recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT05357794·30 enrolled
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
Recruiting·UUniversity of Alabama at Birmingham·Phase 1·NCT05414500·10 enrolled
Combining Topical Imiquimod With Local Radiotherapy for Treatment of Mycosis Fungoides
Recruiting·NNorthwestern University·Phase 1·NCT05838599·25 enrolled
Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome
Active, not recruiting·WWashington University School of Medicine·Phase 1·NCT05944562·24 enrolled
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
Active, not recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04960618·14 enrolled
A Study to Evaluate the Efficacy and Safety of KW-0761 in Chinese Subjects With Mycosis Fungoides or Sézary Syndrome Previously Treated With Systemic Therapy
Active, not recruiting·KKyowa Kirin China Pharmaceutical Co., Ltd.·Phase 4·NCT06285370·23 enrolled
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
Active, not recruiting·MM.D. Anderson Cancer Center·Phase 2·NCT01352520·79 enrolled
Interleukin-2 in Treating Patients With Mycosis Fungoides
Completed·UUniversity of Washington·Phase 1·NCT00002687·30 enrolled
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides
Completed·YYaupon Therapeutics·Phase 2·NCT00535470·100 enrolled
Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma
Completed·National Cancer Institute (NCI)·Phase 2·NCT03063632·28 enrolled
Tretinoin in Treating Patients With Mycosis Fungoides or Sezary Syndrome
Completed·NNorthwestern University·Phase 2·NCT00002479
Photodynamic Therapy in Treating Patients With Refractory Mycosis Fungoides
Completed·MMayo Clinic·Phase 1·NCT03281811·11 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)